Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Why the bump today? Anyone see anything?
nice news out today , 005 up now and breaking out
RespireRx Pharmaceuticals Inc. Announces that Sleep Review has Discussed the RespireRx Dronabinol Obstructive Sleep Apnea (OSA) Program in its June 13, 2022 Edition
Glen Rock, N.J., August 8, 2022 / Globe Newswire – RespireRx Pharmaceuticals Inc. (OTCQ:RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, is pleased to announce that Sleep Review Magazine has published, in its June 13, 2022 edition, a free e-book entitled “How Close Are We to Drug Therapy for Obstructive Sleep Apnea?”, in which it discusses the RespireRx dronabinol OSA program as one of four emerging drug treatments for the treatment of OSA. (https://sleepreviewmag.com/sleep-disorders/breathing-disorders/obstructive-sleep-apnea/how-close-drug-therapy-obstructive-sleep-apnea/).
Editor Sree Roy stated, “For decades, scientists have been searching for a drug therapy for obstructive sleep apnea (OSA)… An oral pharmacologic treatment that keeps airways open during sleep would be a game-changer… An oral pharmacologic treatment would represent a shift in the perception of sleep apnea therapy, likely resolving adherence obstacles associated with medical device-based treatments for many patients. It could also lead to increased willingness among people with OSA symptoms to undergo sleep testing. I wonder how many people who experience excessive daytime sleepiness refuse diagnosis because they are intimidated by currently available sleep apnea treatment options (or at least by their limited knowledge of available treatments)? Sleep specialists too would also welcome another treatment option—more thera¬pies mean more opportunities to find a therapy most compat¬ible to every patient.”
Two Phase 2 clinical trials have been completed demonstrating the ability of dronabinol to significantly reduce the symptoms of OSA and, subject to raising sufficient financing (of which no assurance can be provided) and pending the outcome of an intended meeting with the FDA, RespireRx believes that it will be able to commence a pharmacokinetic study for a recently discovered and to-be-developed formulation followed by a Phase 3 clinical study for the treatment of OSA with the new formulation.
“Dronabinol is being developed by ResolutionRx, a business unit of the RespireRx. It will be my pleasure to discuss with colleagues the latest developments in pharmaceutical cannabinoids and meet with potential business partners,” said Dr. Lippa
followed you, good eye buddy, member marked you
I, for one, am really ready for something good to happen here.
any day now here at bottoms over 0042 we got a ball game
Nail in the coffin?
“Sleep apnea biotech breathes easy with $62.5M financing ahead of PhIII trials for lead oral drug
Lei Lei Wu
News Reporter
Traditional care for obstructive sleep apnea involves CPAP, a cumbersome countermeasure in which patients have air continuously pushed through a mask they have to wear through the night. While there have been improvements to CPAP technology, it has remained the standard of care for obstructive sleep apnea since its invention just over 40 years ago.
However, Cambridge-based biotech Apnimed is now touting that it may have an oral drug that could change that standard, and it has won $62.5 million in Series C funding to fuel an upcoming Phase III trial for said candidate to test that claim.
The biotech initially set out to raise $50 million, but overshot their goal. “That’s always a good sign,” CEO Lawrence Miller said to Endpoints News.”
https://endpts.com/sleep-apnea-biotech-breathes-easy-with-62-5m-financing-ahead-of-phiii-trials-for-lead-oral-drug/
RespireRx Pharmaceuticals Inc. Announces Patent Filings Claiming Novel Lipid Based Formulations for Insoluble Compounds, Including Cannabinoids Such as Dronabinol
BY GlobeNewswire
— 8:00 AM ET 03/23/2022
Glen Rock, N.J., March 23, 2022 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. ( RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, in association with Jeffrey King Managing Attorney at Patent Networks Law Group, is pleased to announce that it has filed a provisional patent application describing novel lipid based formulation technology (LFT) that may be used to improve the solubility and bioavailability of poorly soluble drugs, particularly cannabinoids. Low aqueous solubility is a major problem encountered during the formulation development of drug molecules, with an estimated 70% of current drug research pipelines containing such molecules. Because of its recent use in the formulation of mRNA vaccines for COVID-19, LFT has become a focus for formulation research efforts.
ResolutionRx, our business unit focused on pharmaceutical cannabinoids, has been developing dronabinol (a synthetic form of ?9-tetrahydrocannabinol (“THC”)) that acts upon the nervous system’s endogenous cannabinoid receptors. Dronabinol was approved in 1985 by the FDA as Marinol® for the treatment of AIDS-related anorexia and later for the treatment of chemotherapy-induced nausea and vomiting. Using the commercial form of dronabinol, we have successfully completed two Phase 2 clinical trials demonstrating significant reductions in the major symptoms of obstructive sleep apnea (OSA). However, based on these results and those from pharmacokinetic studies, we have concluded that expansion of dronabinol’s use into OSA and other therapeutic indications will require new, improved formulations. As it is commercially sold, dronabinol is formulated as a sesame oil emulsion in a soft gelatin capsule that suffers from poor and highly variable absorption, low blood levels resulting from rapid and extensive (approximately 80%) first pass liver metabolism, as well as a relatively brief half-life (approximately 2 – 3 hours) requiring high doses in order to achieve sustained, therapeutic blood levels for 4 hours or longer.
In order to circumvent these problems, we have designated certain important properties around which we have created a number of lipid nanoparticle (LNP) formulations of dronabinol, three (3) of which (i) display appropriate water solubility and dissolution to improve absorption, (ii) nano-particle size and resistance to stomach acid conditions in order to reduce first pass liver metabolism and achieve higher and longer blood levels, as well as (iii) stability and ease of manufacturing to support commercial scale. Pending additional financing (availability of which cannot be assured), we plan to test these formulations in animal and human pharmacokinetic (PK) and pharmacodynamic (PD) studies. We believe that the development of a novel, proprietary formulation of dronabinol would not require significantly longer time to market entry compared to what would be required if we were to use the currently available soft gel capsule technology.
“We are very enthusiastic about our new LFT and its potential use in the development of formulations for a broad range of drugs, particularly our new dronabinol formulations. We believe that they may broaden the dronabinol market to include not only OSA but other indications, as well. For example, we believe that while dronabinol is approved for AIDS-related anorexia, its potential use in a broader form of the condition such as anorexia nervosa or avoidant restrictive food intake disorder (ARFID) would benefit from our improved formulations. Since dronabinol already has been approved for AIDS-related anorexia, we believe that a treatment specific formulation of dronabinol could be brought to market rapidly,” said Dr Arnold Lippa, Chief Scientific Officer, Interim President and Interim Chief Executive Officer and Executive Chairman of the Board. “The pharmaceutical use of cannabinoids is beginning to realize commercial expansion and we believe that our new technology can have significant impact.”
RespireRx Pharmaceuticals Inc. Announces Discovery of a New GABAkine Neuromodulator that Protects Against Seizures and Lethality
BY GlobeNewswire
— 8:00 AM ET 03/16/2022
Glen Rock, N.J., March 16, 2022 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. ( RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, is pleased to announce that scientists associated with the Company have published a manuscript detailing the pharmacology of its newest asset, D5-KRM-II-81. The paper titled Metabolism, pharmacokinetics, and anticonvulsant activity of a deuterated analog of the a2/3-selective GABAkine KRM-II-81 in Biopharmaceutics and Drug Disposition. 2022 Feb 22. doi: 10.1002/bdd.2313. Epub ahead of print. PMID: 35194800.
The multidisciplinary team of authors was led by Dr. Jeffrey M. Witkin, a senior research fellow at RespireRx with contributions from academic collaborators at the University of Wisconsin-Milwaukee, Ascension St. Vincent and Indiana University/Purdue University, and the University of Belgrade in Serbia. Authors also include Arnold Lippa, RespireRx Executive Chairman, Interim President and Interim Chief Executive Officer and Chief Scientific Officer. Dr. Lippa is a pioneer in this field since its inception being the first to identify compounds with anxiolytic effects without sedation and to bring them into clinical development (e.g., ocinaplon) while another co-author, Dr. James M. Cook has been inventing key compounds for modulation of GABA-A receptors for several decades.
Since the FDA approval of brexanolone (Zulresso®) for post-partum depression in 2019, several new potentiators of GABA (GABAkines) have entered into the pharmaceutical pipeline. KRM-II-81, originally synthesized by Dr. Cook, is being developed by EndeavourRx, the Company’s neuromodulator business unit, because of its ability to selectively amplify inhibitory neurotransmission at a highly, specific subset of GABAA receptors, thus producing a unique efficacy profile with reduced side effects. The Company currently is focusing on developing KRM-II-81 for the treatment of epilepsy and acute and chronic pain which includes inflammatory and neuropathic pain, which we refer to simply as pain. The findings of broad antiepileptic activity in models of pharmacoresistant epilepsy and in models of pain have encouraged the development of this compound.
D5-KRM-II-81 a structurally related analog is being evaluated by EndeavourRx as a potent, and orally-bioavailable backup that will be used as needed as KRM-II-81 enters its clinical development. Doses of D5-KRM-II-81 as low as 2 mg/kg provided enduring exposure of plasma and brain of rats after oral administration. Importantly, like KRM-II-81, D5-KRM-II-81 completely prevented clonic seizures, tonic seizures, and lethality induced by the GABA receptor antagonist chemoconvulsant pentylenetetrazol. Experimental work in human epileptic brain tissue from patients that are resistant to standard of care antiepileptic medicines is ongoing.
Senior author Dr. Witkin commented, “The antiepileptic potential discovered for D5-KRM-II-81 allows this new orally-bioavailable analog to assist with our drug development efforts in pharmacoresistant epilepsy and pain. Given the large unmet medical need in both of these areas, we are excited to have this new structural analog in our hands.”
Letter to Stockholders and Other Stakeholders: A Brief Summary of Our Progress During Past Twelve Months and a Peek Looking Forward
BY GlobeNewswire
— 8:00 AM ET 03/07/2022
Glen Rock, N.J., March 07, 2022 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. ( RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, is pleased to provide a brief summary of our accomplishments during the prior twelve months as well as a peek looking forward. As we begin this new year, it is appropriate to briefly summarize our progress this past year and describe how we plan to move forward.
To our Stockholders and other Stakeholders:
Thank you for your continued support and shared confidence in the Company’s efforts.
Possibly most visibly, the Company has implemented an internal restructuring plan with the hope of unlocking what we believe is unrealized value, based upon our two research platforms: pharmaceutical cannabinoids and neuromodulators.
ResolutionRx
Cannabinoids/Dronabinol
In ResolutionRx, our pharmaceutical cannabinoid platform, we are developing proprietary compounds based around dronabinol, an already FDA approved drug that targets the CB1 and CB2 receptors of the brain’s endocannabinoid system. While we have successfully completed two clinical trials demonstrating the ability of dronabinol to improve obstructive sleep apnea (OSA), the commercially available form of dronabinol suffers from poor absorption, rapid and extensive liver metabolism and brief duration of action, requiring the use of high doses.
We have been developing novel, proprietary formulations for dronabinol that utilize lipid nanoparticle (LNP) technology and have identified several unique formulations with which we plan to conduct animal and human pharmacokinetic studies. We believe these new LNP formulations have the potential to overcome many of the shortcomings seen with the commercially available form of dronabinol. Overcoming these issues could greatly expand the use of dronabinol for the treatment of disorders that require longer durations of action and less variable blood levels, such as the treatment of obstructive sleep apnea and other conditions.
In support of this program, we have patents pending claiming blood levels, doses, duration of action and intend to submit additional patent applications claiming composition of matter, method of manufacture and method of treatment for dronabinol and other cannabinoids.
EndeavourRx
EndeavourRx, our neuromodulator platform, is made up of two programs: (a) our AMPAkines program, which is developing proprietary compounds that are positive allosteric modulators (“PAMs”) of AMPA-type glutamate receptors and (b) our GABAkines program, which is developing proprietary compounds that are PAMs of GABAA receptors.
AMPAkines
In ongoing studies with Dr. David Fuller, our collaborator at the University of Florida, CX717 and CX1739, our lead clinical stage AMPAkines, continue to show enhancement of motor function in rodents after experiencing spinal injury. Dr. Fuller published the results of last year’s work in two peer-reviewed journals. In particular, the latest paper, published in the Journal of Neurotrauma (http://doi.org/10.1089/neu.2021.0301) describes research conducted for the first time in awake freely moving rats as late as two weeks after having previously undergone unilateral spinal hemi-transection at the C2 spinal level. For the first time, low dose administration of either CX1739 or CX717 was shown to improve not only motor nerve and muscle activity recorded electrophysiologically from the lesioned side, but to significantly improve actual motor functioning and breathing, even under respiratory challenging conditions. The importance of these findings is described in the article by pointing out that the majority of the approximately 500,000 annual spinal cord injury (“SCI”) cases reported globally involve injuries to the cervical spinal cord and, in severe cases, require the use of mechanical ventilation or direct diaphragm pacing to sustain ventilation.
These recent results have provided great impetus to conduct a Phase 2 clinical trial in patients recovering from spinal injury. Clinical sites have been identified and, pending financing, plans have been drafted to update the current CX1739 IND to incorporate a new clinical protocol and conduct the study.
With regard to intellectual property, new patent applications have been filed claiming the use of AMPAkines for the treatment of spinal cord injury and attention deficit hyperactivity disorder.
GABAkines
In our GABAkine program, KRM II-81, our lead GABAkine, is being developed as a potential breakthrough treatment for treatment resistant epilepsy and chronic pain. After our first full year of working with our new research scientists, Drs. Jeffrey Witkin and James Cook, Senior Research Fellows, and Dr. Rok Cerne, Senior Scientist, considerable headway has been made.
Drs. Witkin and Cerne have conducted pharmacology, metabolism, pharmacokinetic and safety studies to be included in future FDA filings. Several articles describing the results of these studies have been published in highly regarded peer reviewed journals, including two review articles and a book chapter detailing the anti-epileptic and analgesic properties of KRM II-81 and its importance in the overall field of GABAkines. Two additional manuscripts have been accepted for publication and an additional manuscript has been written.
Dr. Cook has begun scaling up chemical synthesis of KRM II-81 in order to provide sufficient active pharmaceutical ingredient (API) to begin IND enabling preclinical studies, which we plan to conduct this year pending financing. In addition, substituted analogues of KRM II-81 have been made, particularly a soluble analogue that displays a similar pharmacological profile as KRM II-81.
Corporate Presentations
During 2021, our executives presented at multiple conferences, including BioTech Showcase, OTC Ventures Market Podcast, Life Sciences Investor Conference and the June 2021 Access China Biotech Virtual Investor Conference. Due to the COVID epidemic, these conferences were held virtually. In January 2022, Company executives presented at the 2022 Biotech Showcase and participated in multiple one-on-one meetings with prospective strategic partners, prospective investors and prospective relevant service providers. Company executives intend to participate in additional conferences, and to present in other forums.
Financing
Despite the successes of our research and development team, our major challenge has been to raise substantial equity or equity-linked financing to support our research and development plans, while minimizing the dilutive effect to pre-existing stockholders. At present, we believe that we are hindered primarily by our public corporate structure, our common stock not being listed on a national exchange, and low market capitalization as a result of our low stock price. Our shares are quoted on the OTCQB, the OTC Market’s venture market with the ticker symbol RSPI.
For this reason, the Company has implemented an internal restructuring plan through which our two drug platforms have been reorganized into separate business units and may in the future be organized into private subsidiaries of RespireRx. We believe that by creating one or more subsidiaries to further the aims of ResolutionRx and EndeavourRx, it may be possible, through separate finance channels, to optimize their asset values and make them more attractive for capital raising as well as for strategic transactions.
The Company is also involved in business development efforts (licensing/sub-licensing, joint venture and other commercial structures) with a view to securing strategic partnerships that represent strategic and operational infrastructure additions, as well as cash and in-kind funding opportunities. These efforts have focused on, but have not been limited to, engaging with brand and generic pharmaceutical and biopharmaceutical companies as well as companies with potentially useful formulation or manufacturing capabilities, significant subject matter expertise and financial resources.
No assurance can be given that any financing or business development transaction will come to fruition or that if it does, that the terms will be favorable to the Company.
Regulation A Financing
The Company filed a Form 1-A which included an offering circular that was qualified by The Securities and Exchange Commission on December 13, 2021 and subsequently amended. The offering is of the Company’s common stock and is up to $7.5 million at $0.02 per share and allows for multiple closings until October 31, 2023 unless earlier terminated by the Company. With the current stock price below the offering price, to date, no closings have taken place.
Departure of Mr. Timothy Jones
Mr. Timothy Jones submitted a letter of resignation as the Company’s President and Chief Executive Officer and as a member of the Company’s Board of Directors effective January 31, 2022 subject to the execution of a termination and separation agreement with certain conditions precedent to its final effectiveness, which agreement was executed and all of which conditions have been met. Dr. Lippa has agreed to serve as the Company’s Interim President and Interim Chief Executive Officer until a replacement President and CEO is hired, while retaining his titles as Chief Scientific Officer and Executive Chairman of the Board.
Summary
As you have now read, in the past twelve months, we experienced successes in the furtherance of our research and development despite our financing challenges. With the hoped for success of our ongoing financing efforts, we have plans in place for the following major projects in 2022, which we intend to implement if we achieve the hoped for success of our ongoing financing efforts:
1. conduct animal and human pharmacokinetic studies with three new proprietary dronabinol formulations in order to choose the best one for conducting a Phase 3 clinical efficacy study for OSA in 2023.
2. conduct a Phase 2 clinical trial investigating the effects of CX1739 in patients with SCI.
3. conduct sufficient preclinical IND enabling studies to support an IND for KRM II-81, our lead GABAkine, allowing the start of Phase 1 clinical trials in 2023.
And to our shareholders and stakeholders we are grateful for your support and look forward to a successful 2022.
Sincerely,
Arnold S. Lippa, PhD
Interim President, Interim Chief Executive Officer, Executive Chairman and Chief Scientific Officer
He probably doesn’t have much else to do.
Tomorrow buyers only sellers should’ve gone
I think that investor conference convinced some investors to jump in. I congratulated Margolis this morning on his presentation, which I thought was excellent. He responded to me within 30 minutes.
The recent investor conference presentation by Jeff Margolis is well worth watching. Well done Jeff.
You sir are 100% correct. A decade plus of this. It’s a shell company designed to fleece thru bullshit pr’s and false progression of molecules.
It would appear, by the trading this morning, not many people/investors were impressed by their presentation yesterday !!!
Unfortunately it appears for yers now this outfit is just a meal ticket for the owners.
All my sticks have been in the toilet for months. So, any little tick up is appreciated.
Lol, really - doesn’t take much to make you happy.
I have emailed Jeff 4-5 times over the past year. He has always been helpful and answered my emails within a day.
$RSPI -- I spoke with CFO Mr. Jeff Margolis just a few days ago--he returned my call and we had a great conversation. He is very personable and interested in shareholder concerns.
With the SP being knocked down so low as of late, I had to bring up the Big question, i.e., will there be another R/S coming? His response was "NO RS in the foreseeable future. As a matter of we are currently in the process of raising money. Clinical trials are progressing very well and we anticipate great things to come in in the near-term."
My take is, look for the SP to start climbing again (and holding gains) in the near future. Yeah, I'm a bag holder, but have been accumulating more at this .01-.02 level since my conversation with Jeff. GL
Subpennies coming after this fluff
RespireRx Pharmaceuticals Inc. Announces Publication of Preclinical Results Supporting the Use of AMPAkines in the Treatment of Human Spinal Cord Injury
BY GlobeNewswire
— 8:45 AM ET 11/29/2021
Glen Rock, N.J.,, Nov. 29, 2021 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. ( RSPI ) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, is pleased to announce the publication by Dr. David Fuller (University of Florida) and his colleagues of two new, scientific articles in major, peer-reviewed journals. In these new studies funded by grants from the National Institutes of Health, Dr. Fuller, a long-time RespireRx collaborator, describes the ability of CX1739 and CX717, the Company’s lead AMPAkines, to improve motor nerve activity and muscle function in animal models of spinal cord injury (SCI).
The first paper entitled “Spinally delivered ampakine CX717 increases phrenic motor output in adult rats” was published online ahead of print in the journal Respiratory Physiology and Neurobiology (https://doi.org/10.1016/j.resp.2021.103814) and describes the ability of direct spinal administration of CX717 to increase the amplitude of motor nerve activity on the side ipsilateral (same side) to that in which a unilateral cervical transection had been made to anesthetized and ventilated rats.
Commenting on these results, Arnold Lippa, Ph.D., Chief Scientific Officer and Executive Chairman of the Board of Directors said, “In combination with prior studies, these new results demonstrate that AMPAkines may potentially have broad effects on both the brain and spinal cord to enhance spinal plasticity and improve motor function in patients with different forms of SCI.”
Unlike the above and all prior published articles, the second paper entitled “Ampakines stimulate diaphragm activity after spinal cord injury” was published online ahead of print in the Journal of Neurotrauma (http://doi.org/10.1089/neu.2021.0301) and describes research conducted for the first time in awake freely moving rats as late as two weeks after having previously undergone unilateral spinal hemi-transection at the C2 spinal level. For the first time, low dose administration of either CX1739 or CX717 was shown to improve not only motor nerve and muscle activity recorded electrophysiologically from the lesioned side, but to significantly improve actual motor functioning and breathing, even under challenging conditions. The importance of these findings is described in the article by pointing out that the majority of the approximately 500,000 annual SCI cases reported globally involve injuries to the cervical spinal cord and, in severe cases, require the use of mechanical ventilation or direct diaphragm pacing to sustain ventilation. Also, in confirmation of previously reported results in anesthetized animals, the AMPAkines improved, in awake freely moving animals, the motor facilitation produced by an episode of acute intermittent hypoxia (AIH), a treatment currently used in the rehabilitation of SCI patients.
As Dr. Fuller concluded in this paper, “Our study provides evidence that even lower ampakine doses can effectively stimulate breathing and diaphragm muscle activity in a pre-clinical model of cervical-SCI, with no evidence of adverse effects. Furthermore, ampakine treated animals are capable of increasing respiratory motor drive to a larger degree when challenged, a response often dampened in SCI patients. Lastly, the current data suggest that pairing low-dose and low impact ampakines with even a single brief hypoxia exposure may have value in the context of neurorehabilitation paradigms.”
Dr. Lippa said, “As part of our ongoing AMPAkine collaboration with Dr. Fuller, these exciting new research results add considerable support to the concept that AMPAkines might be a new therapeutic alternative for significantly improving clinical recovery from SCI, when given alone or in combination with other types of rehabilitation. As such, they strengthen our intention to translationally extend this work to human clinical trials.”
It will never go anywhere, but keep its management in salary with other people’s money just like they have for the last 20 years or so.
Market-wide. They really beat these low floaters to a pulp.
I agree. I have never seen such a beating.
This chart is due for a pop. So many low float OTCQB have been beaten down for 10+ months. Crazy.
Really good interview. Margolis represented RSPI quite well.
RespireRx Pharmaceuticals Inc. Announces Video Interview of CFO
BY GlobeNewswire
— 8:45 AM ET 11/04/2021
Glen Rock, N.J., Nov. 04, 2021 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. ( RSPI) , (“RespireRx” or the “Company”) a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, is pleased to announce the public availability of a video interview of its Senior Vice President, Chief Financial Officer, Treasurer and Secretary, Jeff Margolis, by ProActive Investors.
On Thursday, November 4, 2021, a recorded video interview of Jeff Margolis will be available for viewing by the general public by following this link:
Volume.
Then.
Price.
RSPI
1,3 million volume yesterday …any reason?
6 months?
This has been a useless investment for years with management that just seems to a draw a salary from other people’s money while achieving less than nothing.
Company has done nothing since the reverse split a year ago. Can't even come up with some BS or to sell these warrants into.
Probably because the market cap is under $2m for a low float pharma play. Unbelievable how they’ve just driven so many of these into the ground over the past 6 months
So far, nice volume and pps increase. Not sure why, but I like it.
Can we finally get a low float runner here? So sick of everything getting slowly driven into the ground by these algos
Should be an interesting fall. Going to have to release some positive news in order to sell these shares into.
“On August 6, 2021, the Company entered into an investment banking agreement (“PA Agreement”) with Primary Capital LLC (“PC”), pursuant to which PC will act as the Company’s exclusive placement agent for a twelve-month period beginning August 2, 2021, in connection with a contemplated best-efforts securities offering under Regulation A of the Securities Act (“Reg A Offering”). The PA Agreement calls for PC to provide additional investment banking services, both related to the Reg A Offering and independent of the Reg A Offering. The PA Agreement calls for cash fees payable to PC equal to 7% of the gross proceeds from the Reg A Offering associated with investors originated news to sell by PC and 4% of the gross proceeds from the Reg A Offering associated with investors originated by the Company. In addition, the PA Agreement calls for fees payable as warrants equal to 7% of that number of shares of the Company’s common stock with respect to investors originated by PC and 4% for investors originated by the Company. The PA Agreement also provides for a 7% cash and 7% warrant fee for PC-originated investors in any non-Reg A Offering of securities and a cash fee of 5% of the transaction value at the closing of a sale or merger or acquisition transaction. This PA Agreement supersedes all prior contemporaneous negotiations, commitments, agreements and writings with respect to the subject matter of the PA Agreement. The foregoing description of the PA Agreement does not purport to be complete and is qualified in its entirety by reference to the PA Agreement, a copy of which is attached to this report as Exhibit 99.1.
The Company filed a Form 1-A Preliminary Offering Statement with the SEC on August 9, 2021. The SEC has not yet qualified the Reg A Offering. See Note 9. Subsequent Events – Filing of Form 1-A to the Company’s condensed consolidated financial statements as of June 30, 2021.”
We are going to be in this range for awhile unless the company provides some material updates on phase study results. From the lates 10Q.
“On August 9, 2021, the Company filed a Form 1-A Preliminary Offering Statement under Regulation A of the Securities Act with respect to a contemplated Tier 2 offering that may continue for a two-year period. No offering of securities may be made until and unless the offering is qualified by the SEC. The proposed offering is for up to 250,000,000 shares of common stock at a per share offering price of between $0.02 to $0.03, with the exact share price to be set forth by supplement to the Offering Statement, and with gross proceeds not to exceed $7,500,000. On August 12, 2021, the Company received a letter from the SEC informing us that it does not intend to review the Offering Statement, and that upon satisfaction of certain conditions, it will consider qualifying the Offering Statement at the Company’s request.”
Not really but I'm in
Thought so, too. Conviction buying today and big slaps. Quietly. Methodical. Follow the money. The CDEL crooks were on the buy side today.
RSPI
Followers
|
278
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
45380
|
Created
|
12/30/04
|
Type
|
Free
|
Moderators oldstocks DTGoody fly_fisherman jacksonjohn |
RespireRx Pharmaceuticals Inc. and its subsidiaries and business units are discovering and developing medicines for the treatment of psychiatric and neurological disorders, with a focus on treatments that address conditions affecting millions of people, but for which there are few or poor treatment options, including epilepsy, pain, attention deficit hyperactivity disorder (“ADHD”), recovery from spinal cord injury (“SCI”), certain neurological orphan diseases and obstructive sleep apnea (“OSA”). The RespireRx Group is developing a pipeline of new and repurposed drug products based on our broad patent portfolios for two drug platforms: (i) neuromodulators, which include GABAkines and AMPAkines, proprietary chemical entities that positively modulate (positive allosteric modulators or “PAMs”) GABAA receptors and AMPA-type glutamate receptors, respectively, and (ii) pharmaceutical cannabinoids, which include dronabinol, a synthetic compound that acts upon the nervous system’s endogenous cannabinoid receptors and
The RespireRx Group holds exclusive licenses and owns patents and patent applications or rights thereto for certain families of chemical compounds that claim the chemical structures and their uses in the treatment of a variety of disorders, as well as claims for novel uses of known drugs.
EndeavourRx: Neuromodulators
GABAkines. Under a License Agreement with the University of Wisconsin-Milwaukee Research Foundation, Inc. (“UWMRF”) and on behalf of its EndeavourRx business unit, RespireRx has licensed rights to certain selectively acting GABAkines because of their ability to selectively amplify inhibitory neurotransmission at a highly specific subset of GABAA receptors, thus producing a unique efficacy profile with reduced side effects. Preclinical studies have documented their efficacy in a broad array of animal models of interrelated neurological and psychiatric disorders including epilepsy, pain, anxiety, and depression in the absence of or with greatly reduced propensity to produce sedation, motor-impairment, tolerance, dependence and abuse. EndeavourRx currently is focusing on developing KRM-II-81 for the treatment of epilepsy and pain.
KRM-II-81 has displayed a high degree of anti-convulsant activity in a broad range of preclinical studies, including in treatment resistant and pharmaco-resistant models. Not only was KRM-II-81 highly effective in these models, but pharmaco-resistance or tolerance did not develop to its anti-convulsant properties. These latter results are particularly important because pharmaco-resistance occurs when medications that once controlled seizures lose efficacy as a result of chronic use and it is a principal reason some epileptic patients require brain surgery to control their seizures. In support of its potential clinical efficacy, translational studies have demonstrated the ability of KRM-II-81 to dramatically reduce epileptiform electrical activity when administered in situ to brain slices excised from treatment resistant epileptic patients undergoing surgery.
In addition, KRM-II-81 has displayed a high degree of analgesic activity in a broad range of preclinical studies. In intact animal models of pain, the analgesic efficacy of KRM-II-81 was comparable to or greater than commonly used analgesics. At the same time, KRM-II-81 did not display side effects such as sedation and motor impairment, but even more importantly, it did not produce tolerance, dependence, respiratory depression or behavioral changes indicative of abuse liability, which are produced by opioid narcotics and are at the heart of the opioid epidemic.
AMPAkines. Through an extensive translational research effort from the cellular level through Phase 2 clinical trials, RespireRx has developed a family of novel, low impact AMPAkines, including CX717, CX1739 and CX1942 that may have clinical application in the treatment of CNS-driven neurobehavioral and cognitive disorders, spinal cord injury, neurological diseases, and certain orphan indications. Our lead clinical compounds, CX717 and CX1739, have successfully completed multiple Phase 1 safety trials. Both compounds have also completed Phase 2 proof of concept trials demonstrating target engagement, by antagonizing the ability of opioids to induce respiratory depression.
AMPAkines have demonstrated positive activity in animal models of ADHD, results that have been extended translationally into statistically significant improvement of symptoms observed in a Phase 2 human clinical trial of CX717 in adult patients with ADHD. Statistically significant therapeutic effects were observed within one week. We believe AMPAkines may represent a novel, non-stimulant treatment for ADHD with a more rapid onset of action than alternative non-stimulants, such as Straterra® (atomoxetine), and without the drawbacks of amphetamine-type stimulants.
In a series of important studies funded by grants from the National Institutes of Health and published in a number of peer reviewed articles, Dr. David Fuller (University of Florida), a long-time RespireRx collaborator, has demonstrated the ability of CX1739 and CX717, RespireRx’s lead AMPAkines, to improve motor nerve activity and muscle function in a number of animal models of spinal cord injury (SCI).
FORM TYPE | RECEIVED | PERIOD END DATE | REPORT |
---|---|---|---|
8-K | 02/02/2024 | 01/30/2024 | PDFRTFHTMLXLS |
8-K | 01/22/2024 | 01/18/2024 | PDFRTFHTMLXLS |
8-K | 12/11/2023 | 12/06/2023 | PDFRTFHTMLXLS |
10-Q | 11/17/2023 | 09/30/2023 | PDFRTFHTMLXLS |
NT 10-Q | 11/14/2023 | 09/30/2023 | PDFRTFHTML |
8-K | 10/12/2023 | 10/09/2023 | PDFRTFHTMLXLS |
8-K | 10/02/2023 | 09/26/2023 | PDFRTFHTMLXLS |
10-Q | 08/21/2023 | 06/30/2023 | PDFRTFHTMLXLS |
NT 10-Q | 08/14/2023 | 06/30/2023 | PDFRTFHTML |
8-K | 08/09/2023 | 08/03/2023 | PDFRTFHTMLXLS |
DISCLAIMER:
Nothing in the contents transmitted on this board should be construed as an investment advisory, nor should it be used to make investment decisions.
There is no express or implied solicitation to buy or sell securities.
The author(s) may have positions in the stocks or financial relationships with the company or companies discussed and may trade in the stocks mentioned.
Readers are advised to conduct their own due diligence prior to considering buying or selling any stock.
All information should be considered for information purposes only.
No stock exchange has approved or disapproved of the information here
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |